MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Lung Cancer Treatments and Mutations
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,464 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,464 works in the cohort · of 4,299,418page 2 of 50

Labels cover 16 of 2,464 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,464 of 2,464 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline
Natasha B. Leighl, Natasha Rekhtman, William A. Biermann, James Huang, Mari Mino–Kenudson, Suresh S. Ramalingam +3 more
2014· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaresearchconsensus · none
290
citations
affunlabeled
Prognostic factors in cancer
Mary Gospodarowicz, Brian O’Sullivan
2003· review· en· Seminars in Surgical Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
289
citations
aboutno affunlabeled
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1<sup>st</sup> line or 2<sup>nd</sup> line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial
Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Ee Hong Tan, Vera Hirsh, S. Thongprasert +4 more
2004· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaresearch+metaepi_narrowconsensus · none
263
citations
aboutno affunlabeled
Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group
Cesare Gridelli, Ciro Gallo, Frances A. Shepherd, Alfonso Illiano, Francovito Piantedosi, Sergio Robbiati +15 more
2003· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaresearchconsensus · none
245
citations
fundno affunlabeled
New molecularly targeted therapies for lung cancer
Sophie Sun, Joan H. Schiller, Monica Spinola, John D. Minna
2007· review· en· Journal of Clinical Investigation· Medicine
distilled prediction:candidate · noneconsensus · none
205
citations
← previousnext →

How this was built: Screen · Findings · About